Use of FLJ25416 gene
Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.
1. A method of treating colon, lung, or liver cancer expressing an FLJ25416 gene having the sequence of SEQ ID NO: 1 in a subject, said method comprising administering to the subject an effective amount of an siRNA or shRNA inhibitor of the expression of the FLJ25416 gene to inhibit the expression of the gene and thereby inhibit the proliferation of colon, lung, or liver cancer cells in the subject, wherein the siRNA or shRNA inhibitor is sufficiently complementary to SEQ ID NO: 2 to anneal to the mRNA transcript of the gene to result in RNA interference in vivo.
2. The method of claim 1 , wherein said siRNA inhibitor comprises the complement of SEQ ID NO: 2.
3. The method of claim 1 , wherein said shRNA inhibitor is encoded by SEQ ID NO: 9.